The myth of the "medical beauty blue-chip" is facing a severe test. In late March, Imeik Technology Development Co.,Ltd. reported its first annual results since listing that showed declines in both revenue and net profit. This leading medical aesthetics company, once hailed as a "money-printing machine," has abruptly slammed the brakes after years of rapid growth. The significant deterioration in performance has not only surprised the market but also exposed three major underlying concerns beneath its glossy exterior.
The company's two primary revenue pillars, solution-based and gel-based injectable products, once formed its most robust competitive moat. However, over the past year, both product lines have lost momentum, experiencing substantial declines in revenue. Taking "Hitime," which once dominated the neck wrinkle repair market, as an example: with competing products from rivals like Bloomage BioTechnology successively gaining approval, the exclusive monopoly in this niche segment has been completely broken. Competition is even fiercer in the regenerative medical aesthetics field, where "youth restoration" products have shifted from a market with a "few players" to one of "multi-party competition," rapidly diluting Imeik's differentiated advantage in this area.
Industry experts point out that the revenue decline in Imeik's core product lines signals the end of the golden era where upstream medical beauty companies could monopolize niche segments with a single "blockbuster product." As hyaluronic acid or regenerative products enter a phase of存量博弈 (competition for existing market share), technological barriers appear increasingly fragile in the face of homogenized competition and market penetration into lower-tier cities.
In a bid to seek new growth drivers, Imeik completed the acquisition of South Korea's REGEN last year, attempting to introduce its well-known "youth restoration" product into the Chinese market. However, this international move, which was highly anticipated, has not only failed to contribute immediately to performance but has also dragged the company into a serious legal dispute. The former exclusive distributor in mainland China has initiated arbitration, claiming compensation exceeding one billion yuan. More critically, the arbitral institution has issued a provisional decision prohibiting Imeik's subsidiary from independently selling the product in mainland China pending the final arbitration award. This means that despite the significant investment in the acquisition, Imeik cannot currently commercialize this internationally popular product domestically. The expected growth driver is on hold, while the company simultaneously faces potential risks of substantial compensation payouts.
This acquisition has also led to a sharp increase in the company's goodwill. If the arbitration outcome is unfavorable, a potential goodwill impairment could create a new profit black hole. Experts caution that while international mergers and acquisitions are a shortcut for Chinese medical aesthetics firms to access cutting-edge technology, high premiums and legal risks are constant companions. Overseas acquisitions must focus not just on "buying assets" but also on the legal rigor of underlying contracts and compliance in cross-border governance.
In conclusion, regarding the performance decline, Imeik attributes it to the dual impact of the macroeconomic environment and industry competition. However, a deeper issue remains: as hyaluronic acid and regenerative products enter a phase of存量博弈 (competition for existing market share), can the former "medical beauty blue-chip" find a new growth engine? Its botulinum toxin product has only recently been approved, semaglutide is still in the clinical stage, and its overseas acquisition is mired in legal troubles. As a medical strategy consultant stated, "The era of high gross margins is over, requiring more refined cost control." The year 2025 stands as a watershed moment for Imeik since its IPO. The market is watching closely to see if this former medical aesthetics giant can overcome the challenges before it.
Comments